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ABSTRACT
Testicular germ-cell tumors (TGCTs) of adolescents and adults origi-
nate from intratubular germ cell neoplasia (ITGCN), which is composed
of the malignant counterparts of embryonal germ cells. ITGCN cells are
characterized, among others, by the presence of stem cell factor receptor
c-KIT. Once established, ITGCN will always progress to invasiveness.
Approximately 2.5–5% of patients with a TGCT will develop bilateral
disease and require complete castration, resulting in infertility, a need for
lifelong androgen replacement, and psychological stress. To date, the only
way to predict a contralateral tumor is surgical biopsy of the contralateral
testis to demonstrate ITGCN. We did a retrospective study of 224 unilat-
eral and 61 proven bilateral TGCTs (from 46 patients, in three independ-
ently collected series in Europe) for the presence of activating c-KIT codon
816 mutations. A c-KIT codon 816 mutation was found in three unilateral
TGCT (1.3%), and in 57 bilateral TGCTs (93%; P < 0.0001). In the two
wild-type bilateral tumors for which ITGCN was available, the preinva-
sive cells contained the mutation. The mutations were somatic in origin
and identical in both tumors. We conclude that somatic activating codon
816 c-KIT mutations are associated with development of bilateral TGCT.
Detection of c-KIT codon 816 mutations in unilateral TGCT identifies
patients at risk for bilateral disease. These patients may undergo tailored
treatment to prevent the development of bilateral disease, with retention
of testicular hormonal function.
INTRODUCTION
TGCTs7 of adolescents and adults, the seminomas and nonsemino-
mas (1), are the most frequent malignancies in Caucasian males
15–40 years of age (2). Several risk factors have been reported,
including family history, undescended testis, and a previous TGCT
(see Ref. 3 for review). The initiating event, leading to ITGCN, also
known as carcinoma in situ (4), occurs during intrauterine develop-
ment (5, 6). ITGCN cells indeed show characteristics of embryonic
germ cells, i.e., PGCs/gonocytes, including the presence of the stem
cell factor receptor c-KIT (7) and OCT3/4 (POU5F1; Ref. 8).
Between 2.5 and 5% of TGCT patients will develop contralateral
disease. Approximately half of the second tumors are diagnosed
within the first 5 years after the initial diagnosis. However, 25% of
patients present with the second tumor 10 years after diagnosis of the
first, and the latency period can be up to 20 years (9, 10). This
illustrates the need for a long follow-up of all TGCT patients. To date,
no predictor for risk of bilateral TGCT is available, except an open
surgical biopsy for the identification of ITGCN (11). Because of
possible complications, application of this procedure is not recom-
mended for all patients with unilateral disease (12). However, early
diagnosis of contralateral ITGCN has clinical relevance. This is illus-
trated by the fact that the lifetime risk for TGCT is similar to the
incidence of ITGCN in the general population, i.e., no spontaneous
regression of ITGCN occurs (13). Moreover, 50% of patients with
ITGCN in the contralateral testis will develop an invasive TGCT
within 5 years after diagnosis of ITGCN (14). Development of a
second invasive TGCT will, in the majority of patients, require
complete castration, resulting in need for hormone supplementation
and psychological burden. ITGCN can be cured by low-dose irradi-
ation, thereby preventing the development of an invasive tumor with
preservation of the hormonal function in most patients (15, for re-
view).
In view of this, there is clinical need for a predictive noninvasive
test to identify TGCT patients at risk for bilateral disease. Here we
report the novel finding that the presence of an activating codon 816
c-KIT mutation in a TGCT is associated with development of a
contralateral TGCT. An activating c-KIT codon 816 mutation, encod-
ing an Asp816His, has been reported previously in a single TGCT
(16).
MATERIALS AND METHODS
Sample Handling and Characterization. The fresh tumors were collected
in the southwestern part of the Netherlands. Representative parts of the tumors
and adjacent testicular parenchyma were snap frozen or fixed overnight in 4%
formalin for paraffin embedding. Diagnosis was made according to the rec-
ommendations of the WHO (1). This was confirmed by immunohistochemistry
for the presence of OCT3/4, as described previously (8).
Additionally, two independent series were included, one collected in Hun-
gary, consisting of DNA from 18 tumors (all second tumors), and a series of
6 unilateral TGCT with matched contralateral ITGCN-containing biopsies,
collected in Norway.
From multiple 3- to 5-m-thick paraffin sections, tumor and ITGCN cells
were dissected after deparaffinization with a sterile scalpel blade under direct
microscopic visualization. Multiple 20-m-thick tissue sections from frozen
samples were used. The cells were microdissected with the Arcturus Pixcell II
system, after which DNA was isolated (digestion with 1 mg/ml proteinase K).
REMS AatII PCR. A modified 3 primer (exon 17R) was used to generate
an AatII recognition site encompassing codon 816 (see Fig. 1). The presence
of a mutation at this codon will result in disruption of the recognition site for
the restriction endonuclease, leading to nondigested amplification products.
Amplification was performed by PCR analysis using primers exon 17F (5-
TGTATTCACAGAGACTTGGCA-3) and exon 17R (5-TAATTAGAAT-
CATTCTTGACG-3), which yielded a 106-bp product. Reactions were carried
out in a volume of 30 l containing 2.3 mM MgCl2, 10 mM Tris-HCl (pH 8.3),
50 mM KCl, 1 M deoxynucleotide triphosphates, 0.33 M each primer, and
1.0 unit of Taq DNA polymerase (Qiagen). For each reaction, 50 ng of input
DNA was used. PCR amplification was performed on a MJ Research Ther-
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mocycler with the following conditions: 95°C for 5 min of initial heat dena-
turation and 35 cycles of 95°C for 30 s, 45°C for 30 s, and 72°C for 30 s.
Amplification products (10 l) were digested to completion with 5 units of
AatII (Fermentas) at 37°C overnight, yielding 85- and 21-bp fragments for
wild- type amplification products. In contrast, in the presence of a mutation, no
cleavage occurred.
The amplification products were cloned into a pCR TOPO-II vector and
transformed in TOPO 10 One-Shot cells by use of the TOPO TA cloning kit
(Invitrogen, Breda, The Netherlands). Inserts were sequenced (at least 10) on
a Licor automated sequencer using a M13 Reverse primer.
SNuPE. Amplification was performed with primer set exon 17F (5-TG-
TATTCACAGAGACTTGGCA-3) and exon 17R6 (5-GTTTCCTTTAAC-
CACATAATTAG-3) and yielded products 122 bp in length (for conditions,
see above, with an annealing temperature of 56.5°C; see Fig. 2, left panel).
Amplified fragments were purified by electrophoresis on a nondenaturing 10%
polyacrylamide gel containing ethidium bromide, after which the fragments
were dissected and eluted with elution buffer (containing 0.5 M ammonium
acetate, 1 mM EDTA) at 37°C overnight. The SNuPE reaction (total volume,
10 l) contained 1.0 l of extracted PCR product, 1 pmol of reverse Y/Hr
(5-ATAATTAGAATCATTCTTGATGT-3) SNuPE primer for D816Y and
H, and, for D816V, reverse primer D816Vr (5-CATAATTAGAATCATTCT-
TGATG-3); 10 mM Tris-HCl (pH 8.3); 50 mM KCl; 1.5 mM MgCl2; 0.75 units
of Taq DNA polymerase (Qiagen); and 0.2 l of [-32P]dATP or dGTP (3000
Ci/mmol; Amersham). Conditions for extension were 1 cycle of 95°C for 1
min, 58°C for 30 s, and 72°C for 30 s. The samples were analyzed by
electrophoresis on a 15% denaturing polyacrylamide gel and subsequent
autoradiography. As controls, cloned fragments of both proven mutated and
wild-type sequences were used.
RESULTS
To screen for codon 816 mutations, we applied a REMS PCR
approach to 110 primary consecutively collected TGCTs, including
seminomas and nonseminomas (Fig. 1, left panel). Four TGCTs
(3.6%) demonstrated indigestible products. The presence of a muta-
tion was confirmed by sequencing of cloned amplification products
(examples in Fig. 1, right panel) and the SNuPE method (Fig. 2, left
panel). Two tumors showed an Asp816Val and two an Asp816Tyr.
The latter two were from patients diagnosed with bilateral disease.
Both TGCTs contained the same mutation (Table 1, cases 1 and 2).
Additionally, 20 proven bilateral TGCTs (for which 33 tumors were
available; Table 1), were investigated as were 116 randomly picked
unilateral cases, all collected in the Netherlands. Although only two of
the unilateral TGCTs tested in the second screen (1.7%) showed a
mutation (Asp816Val), all but two tumors (94%; see below) from the
bilateral cases contained a mutation (Table 1; Fig. 2, right panel). All
matched tumors showed concordant findings, although an additional
mutation was found in one of the tumors in seven independent cases.
Two tumors (cases 15I and 19II) did not show a mutation (Table 1),
even after microdissection of tumor cells. Adjacent testicular paren-
chyma containing ITGCN was available for 10 of the bilateral tumors,
including the 2 lacking a mutation. The ITGCN cells were microdis-
sected and subsequently investigated. All samples showed at least one
mutation, including the two samples adjacent to the wild-type tumors,
most often the same mutation that was present in the matched invasive
tumor (Table 1; Fig. 2, right panel). This indicates that the genetic
change is present in the preinvasive lesion but can be lost on invasive
growth. In three cases, semen obtained before surgical removal of the
affected testis was investigated, and the same mutation was identified
as present in ITGCN (Table 1).
Peripheral blood DNA from four patients with a c-KIT mutation in
the tumor (two with bilateral disease), collected before surgical re-
moval of the affected testis, was available and investigated. None of
Fig. 1. Left, schematic representation of the REMS-PCR method to amplify both wild-type (WT) and codon 816-mutated (M) c-KIT alleles. Exon 17F and 17R primers are used,
in which a mismatch nucleotide (C instead of T; indicated by ) is included at position 1 of codon 817. The amplification products (106 bp in length) derived from wild-type alleles
are digested to completeness by the restriction endonuclease AatII (leading to fragments of 85 and 21 bp), whereas the amplification products containing a genetic change at codon
816 are not digested. The restriction endonuclease recognition site is indicated by a double arrow. Representative examples of the size-separated amplification products by gel
electrophoresis before and after AatII digestion are shown. Note the presence of the digested 85-bp product in the wild-type samples (Lanes 1–3) and both the digested and undigested
products (106 bp) in the mutant (Lane 4). Lane M, marker. Right, examples of the automated sequence analyses of cloned amplification products of the REMS PCR. Wild-type (GAG)
and mutated alleles (GTC, valine; GAC, tyrosine; CAC, histidine) are shown. Note the G at position 1 of codon 817, introduced by the modified primer (exon17R), indicated by .
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them contained the mutation (see Table 1). In addition, no mutation
was found in the normal testicular parenchyma lacking ITGCN in the
patients with bilateral disease. In 13 invasive TGCTs and in all
ITGCN samples, the mutation was found only after microdissection
(Table 1).
To confirm the association between c-KIT codon 816 mutations and
bilateral TGCT, we investigated an independent series of 18 TGCT of
patients with bilateral disease, for whom only DNA from the second
tumor was available (see Table 2, top). Sixteen of the samples con-
tained a mutation in codon 816 (89%). In addition, an independent
series of six unilateral invasive TGCTs and matched ITGCNs of the
contralateral testis (obtained by biopsy) were studied (see Table 2,
bottom). Of one unilateral invasive tumor, only the ITGCN cells were
available. No invasive TGCT was present in any of the biopsied
testes. All primary TGCTs as well as the matched ITGCN of the same
testis showed a mutation. All contralateral ITGCNs showed at least
the same genetic change as the primary invasive tumor and matched
ITGCN. Multiple mutations were found in four ITGCN samples,
whereas a single mutation was detected in two.
DISCUSSION
Our data convincingly show that mutations affecting codon 816 of
c-KIT are associated with development of bilateral TGCT. This was
proven by investigation of three independently collected series of
bilateral TGCTs. Although only a minority of unilateral TGCTs
contained a codon 816 mutation (1.3%), it was present in the majority
of the series of bilateral TGCTs (95, 89, and 100%, respectively;
P  0.0001, Fisher’s exact test). This finding is of relevance to
understand the biology of TGCT, because the c-KIT/stem cell factor
system is crucial for the proper migration and survival of PGCs (see
Ref. 17 for a review). The stem cell factor is also one of the crucial
components for in vitro survival of mouse and human PGCs (17), as
well as human seminoma cells (18). c-KIT is a tyrosine kinase
receptor of the subclass III family, for which the stem cell factor is the
receptor. Binding of the ligand to the receptor results in receptor
homodimerization and subsequent tyrosine kinase activity, leading to
phosphorylation of various substrates. Downstream signaling path-
ways include proteins involved in regulation of apoptosis and cell
proliferation (see Ref. 19 for a review). The codon 816 mutations
result in a constitutional kinase-activated protein and phosphorylation
of tyrosine residues, although with a change in the catalytic activity
and substrate specificity compared with the wild-type receptor. No
differences have been identified to date between the various types of
codon 816 mutations regarding their biochemical properties.
This study shows that the c-KIT mutation in TGCTs is somatic in
origin, in accordance to the findings of the International Testicular
Cancer Linkage Consortium.8 Because of the presence of similar
changes in the matched bilateral TGCTs, the findings support the
model that bilateral TGCTs are monoclonal in origin. Although clin-
ically unlikely (9, 10), the second TGCT might be a metastasis of the
primary tumor to the contralateral testis. This possibility was excluded
in our study by our investigation of six cases of unilateral invasive
TGCT with matched contralateral ITGCN (without invasive disease),
the latter identified by surgical biopsy. These findings favor the model
8 E. A. Rapley, S. Hockley, W. Warren, L. Johnson, R. Huddart, G. Crockford, et al.
Somatic mutations of KIT in familial testicular germ cell tumours, submitted for publi-
cation.
Fig. 2. Left, schematic representation of the SNuPE method for detecting mutated codon 816 c-KIT alleles. The presence of a GTC (encoding a valine; V), a GAC (encoding a
tyrosine; Y), or a CAC (encoding a histidine; H) instead of a GAC (encoding an aspartate; wild type; WT) is specifically detected. The SNuPE primers are indicated as dotted lines.
A radioactively labeled A nucleotide (underlined) is incorporated at position 2 of codon 816 in case of a GTC sequence and at position 1 in case of a GAC sequence, whereas a
radioactively labeled G is incorporated at position 1 in case of a CAC sequence. None of these primers will lead to extension of an A or G nucleotide if only wild-type amplification
products are present. Right, examples of detected mutations (V, Y, and H, indicated by an arrow) are shown. Both wild-type (WT) and mutated samples are indicated. Samples, both
tumor (T) and precursor cells (ITGCN), are investigated without (Total) and after microdissection (Micro). In addition, cloned amplification products (plasmid) of wild-type or mutated
alleles (Yplasmid, tyrosine; Vplasmid, valine; Hplasmid, histidine), as well as H2O () are included as controls. The codes for the samples correspond to the codes used in Table 1.
For some samples, the results obtained from DNA isolated from frozen (F) and paraffin-embedded (P) tissue are shown.
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that the mutation occurs during or before migration of PGCs to the
genital ridge.
Of the 224 unilateral TGCTs, 4 (1.8%) showed a mutation. One of
these patients developed a bilateral TGCT (Table 1, case 3) during the
period of this project. The second TGCT in this patient was diagnosed
9 years after the first. To date, none of the other three patients
developed a second tumor. No contralateral biopsy was done. The
ages of these patients at initial diagnosis were 26, 34, and 41 years,
being 10, 7, and 7 years ago, respectively. As indicated based on the
data presented in Table 1, the time between diagnosis of the first and
second TGCT in a single patient is, on average, 7.0 years but can be
up to 20 years, in accordance with published data (9, 20). Because of
the knowledge that no spontaneous regression of ITGCN occurs (13),
these patients will be kept under close examination.
At least two of the patients with a bilateral TGCT from our
investigated series (Table 1, case 8; Table 2, top, case 1) had an
affected brother (for which the tumors were not available for analy-
ses). This indicates that the presence of a c-KIT mutation is not
restricted to sporadic TGCT, which was confirmed in the study of the
International Testicular Cancer Linkage Consortium.8 That study
showed no germline mutations in 240 pedigrees of families with at
least two patients with TGCT. In addition, a significantly higher
number of c-KIT mutations were found in bilateral versus unilateral
TGCT. The finding that not all bilateral TGCTs in the familial context
contained a mutation might be because of the familial predisposition.
Familial predisposition might be an alternative mechanism to a c-KIT
mutation for promotion of bilateral disease. Alternatively, it might be
attributable to the fact that no ITGCN was investigated. We showed
that although the invasive TGCT could lack a mutated c-KIT, the
mutation is present in the precursor lesion. Further investigation could
shed light on the possible role of common intrauterine etiological
factors in the development of TGCT (21).
We demonstrated that a mutation of codon 816 in c-KIT is associ-
ated with development of bilateral TGCT. These kinds of mutations
Table 1 Summary of the clinical data and mutation analysis of c-KIT codon 816 in bilateral TGCTs
The mean age of the patients at time of clinical diagnosis of the first tumor was 31.9 years (range, 15–56 years); the mean age at diagnosis was 36.6 years for seminomas and 23.8
years for nonseminomas. The mean age at diagnosis of the second tumor was 38.3 years (range, 23–59 years; mean age, 40.3 years for seminomas and 28.5 years for nonseminomas).
The mean difference in age between clinical presentation of the first and second (asynchronous) tumors was 7.0 years (range, 1–19 years). These figures are in accordance with published
data (see Ref. 9 for a review).
Case Tumora Age (years) Histologyb Mutationc ITGCN Semen PBLd Remarks
1 I 51 SE D816Y
II 56 SE D816Y D816Ye
2 I 32 SE D816Y D816Ye
II 35 SE D816Y D816Y
3 I 26 SE D816V During project f
II 35 SE D816YVe WT
4 I 24 NS NA
II 37 SE D816Y D816Y
5 I 28 NS D816YHe
II 44 SE D816Y
6 I 33 SE D816Y
II 37 SE D816Y D816Ye
7 I 25 NS D816Y D816Y
II 35 NS D816Y
8 I 35 SE NA Familialg
II 54 SE D816YVHe
9 I 15 NS D816YVHe
II 24 NS D816Y D816Ye
10 I 37 SE D816Y
II 47 SE D816YH
11 I 41 SE NA
II 51 SE D816YVe
12 I 35 SE D816YVe WT
II 35 SE D816Y WT
13 I 28 NS D816Y
II 30 SE D816Y
14 I 35 SE D816YVe
II 44 SE D816V
15 I 22 NS WT D816YVHe
II 23 NS D816Y
16 I 31 SE D816YVHe
II 34 SE D816V D816YVe
17 I 56 SE NA
II 59 SE D816Y
18 I 29 SE NA
II 32 NS D816YVe
19 I 19 NS NA
II 25 SE WT D816YVe
20 I 36 SE D816YVHe D816YVe
II 36 SE D817H
21 I 29 NS NA
II 33 SE D816YVe
22 I 35 SE D816YVe D816YVe
II 36 SE D816YVe D816YVe
a I, first tumor; II, second tumor.
b SE, seminoma; NS, nonseminoma. Tumors containing both seminomatous and nonseminomatous components (cases 4 I, 5 II, 6 I, 15 II, and 21 I) were classified as
nonseminomatous.
c Y, tyrosine (TAC); V, valine (GTC); H, histidine (CAC); NA, not available; WT, wild type (aspartate, D; GAC).
d PBL, peripheral blood.
e Mutation was detected only after microdissection.
f Became bilateral during the course of the project.
g Familial disposition.
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have been found previously in a single TGCT and an ovarian germ
cell tumor (16). In addition, they have been identified in human
mastocytosis, acute myeloid leukemia, and sinonasal natural killer/T-
cell lymphoma (see Ref. 19 for a review). The activating mutations, as
reported in gastrointestinal stromal tumors, do not affect exon 17 but
do affect exons 9 or 11. These mutations result in ligand-independent
receptor dimerization, leading to kinase activity on the receptor. This
is in contrast to the intrinsic kinase activity in the case of codon 816
mutations. The tyrosine kinase inhibitor STI571 (imatinib mesylate;
Gleevec) has been found to be effective for treating gastrointestinal
stromal tumors. In contrast, this small molecule does not inhibit c-KIT
containing codon 816 mutations (see Ref. 19 for a review), as found
in TGCT (Ref. 16 and this study).
The activating mutations detected in TGCT likely occur during
early embryonal development. Therefore, c-KIT codon 816 mutations
are highly penetrant genetic changes for embryonic germ cells, lead-
ing to development of bilateral TGCT. The presence of such a
mutation in a TGCT indicates a high risk for bilateral disease. Because
of the occasional absence of the mutated allele in the invasive tumor,
analysis of both the invasive tumor and the ITGCN is recommended.
This finding could modify present management and counseling of
patients with a unilateral TGCT, making open surgical biopsy for
identification of contralateral ITGCN superfluous in the majority of
patients with a unilateral TGCT. It could facilitate improved treatment
of patients prone to develop bilateral disease, either by a watch-and-
wait strategy or by use of localized low-dose gonadal irradiation,
which should not affect hormonal function in the majority of patients
(15). It remains to be investigated whether specific tyrosine kinase
inhibitors, such PP1 and PP2 (22), might be effective in chemopre-
vention of progression of contralateral ITGCN to an invasive TGCT
in patients with a clinically proven unilateral TGCT with a c-KIT
codon 816 mutation.
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Table 2 Summary of c-KIT codon 816 mutation analysis in two independent series of
proven bilateral TGCTs
For the results in the top portion, only the second tumor was investigated (collected in
Hungary). In the bottom portion, the primary tumor with adjacent ITGCN, as well as
contralateral ITGCN, were identified based on biopsy analysis (collected in Norway) see
Table 1 for further explanations.
Case Age (years) Histology Mutation
1a 24 SEb D816V
2 41 NS D816YV
3 42 SE D816YV
4 35 SE D816V
5 25 SE D816V
6 22 NS WT
7 40 SE D816YV
8 26 SE D816YV
9 36 NS D816YV
10 20 NS D816V
11 28 NS D816V
12 52 SE D816V
13 33 SE D816Y
14 41 SE D816V
15 45 SE WT
16 35 SE D816YV
17 23 NS D816Y
18 47 SE D816V
Contralateral biopsy
with ITGCN
1 ITGCN D816V D816YV
SE D816YVH
2 SE D816YV D816Y
3 ITGCN D816YV D816V
4 ITGCN D816YV D816YVH
SE D816YV
5 SE D816YV D816YV
6 SE D816V D816YV
a Familial.
b SE, seminoma; NS, nonseminoma.
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